TrialJournal of gynecologic oncology2021

Tailored-dose chemotherapy with gemcitabine and irinotecan in patients with platinum-refractory/resistant ovarian or primary peritoneal cancer: a phase II trial.

Shinichi Tate et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.